amikacin + nafcillin

Amikacin + nafcillin is a combination of two antibiotics used for the treatment of severe bacterial infections, particularly those caused by both Gram-negative and Gram-positive organisms. Amikacin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, leading to cell death. It is especially effective against resistant Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter species. Nafcillin is a beta-lactamase-resistant penicillin (antistaphylococcal penicillin) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins; it is primarily used for infections caused by methicillin-sensitive Staphylococcus aureus (MSSA) and other susceptible staphylococci. The combination may be considered in clinical scenarios where mixed or complicated infections are suspected or confirmed, such as endocarditis or bacteremia involving both susceptible staphylococci and resistant Gram-negative pathogens.